Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...

The approval follows a heightened regulatory focus on CAR-T cell therapy safety this year. In April, the FDA mandated boxed ...

The presentation at SITC titled, ‘Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced ...

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, ...

Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...

India is witnessing a surge in cancer cases, with an estimated 800,000 new diagnoses annually. The increase is attributed to ...

The scientific program's plenary sessions cover: Novel therapies and international considerations in access and regulatory approval Economics of novel cellular therapies Transplantation and cell ...

Underscoring how trials can benefit all members of a community and discussing spirituality may improve enrollment of Black ...

A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in treatment-refractory ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic ...